Agonists and antagonists of 5-HT2 receptors

  • E. J. Mylecharane
Part of the Developments in CardioCardiovascular Pharmacology of 5-Hydroxytryptamine book series (DICM, volume 106)


In the context of an update on new drugs used in the characterization of functional receptors for 5-hydroxytryptamine (5-HT), a review such as this on 5-HT2 receptor agonists and antagonists needs to address the criteria currently used to classify these receptors, and to consider the validity of these criteria in the light of the relevant data available on functional actions. In particular, any evidence suggesting heterogeneity within this functional receptor classification needs to be evaluated, thus quantitative functional data obtained in vitro for several 5-HT2 receptor antagonists in a range of tissues containing 5-HT2 receptors have been considered in some detail. Comparisons have also been made with data obtained in ligand binding studies. The question of specificity has also been briefly considered, and some recently developed 5-HT2 receptor agonists and antagonists have been discussed.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bradley PB, Engel G, Feniuk W, Fozard JR, Humphrey PPA, Middlemiss DN, Mylecharane EJ, Richardson BP, Saxena PR (1986): Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology25: 563–576.PubMedCrossRefGoogle Scholar
  2. 2.
    Peroutka SJ, Snyder SH (1979): Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H] spiroperidol. Mol Pharmacol16: 687–699.PubMedGoogle Scholar
  3. 3.
    Leysen JE, Awouters F, Kennis L, Laduron PM, Vandenberk J, Janssen PAJ (1981): Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors. Life Sciences28: 1015–1022.PubMedCrossRefGoogle Scholar
  4. 4.
    Feniuk W, Hare J, Humphrey PPA (1981): An analysis of the mechanism of 5-hydroxytryptamine-induced vasopressor responses in ganglion-blocked anaesthetized dogs. J Pharm Pharmacol33: 155–160.PubMedCrossRefGoogle Scholar
  5. 5.
    Colpaert FC, Niemegeers CJE, Janssen PAJ (1982): A drug discrimination analysis of lysergic acid diethylamide (LSD): in vivo agonist and antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, a LSD-antagonist. J Pharmacol Exp Ther221: 206–214.PubMedGoogle Scholar
  6. 6.
    Glennon RA, Young R, Rosecrans JA (1983): Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists. Eur J Pharmacol91: 189–196.PubMedCrossRefGoogle Scholar
  7. 7.
    Friedman RL, Barrett RJ, Sanders-Bush E (1984): Discriminative stimulus properties of quipazine: mediation by serotonin2 binding sites. J Pharmacol Exp Ther 228: 628–635.PubMedGoogle Scholar
  8. 8.
    Tricklebank MD (1985): The behavioural response to 5-HT receptor agonists and subtypes of the central 5-HT receptor. Trends Pharmacol Sci6: 403–407.CrossRefGoogle Scholar
  9. 9.
    Roberts MHT, Davies M (1989): In vivo electrophysiology of receptor subtypes mediating the central nervous system actions of 5-hydroxytryptamine, pp. 70–76 in: Mylecharane EJ, Angus JA, de la Lande IS, Humphrey PPA (eds), Serotonin: Actions, Receptors, Pathophysiology. Proceedings of Satellite Symposium of the IUPHAR 10th International Congress of Pharmacology, Heron Island, 4–6 September 1987. London: Macmillan.Google Scholar
  10. 10.
    Davies MF, Deisz RA, Prince DA, Peroutka SJ (1987): Physiological and pharmacological characterization of the response of guinea pig neocortical neurons to serotonin. Soc Neurosci Abstracts 13:801.Google Scholar
  11. 11.
    Gurevich N, Wu PH, Carlen PL (1987): Complexities of serotonin and serotonin antagonist interactions measured intracellularly in hippocampal CA, neurons. Soc Neurosci Abstracts13: 1650.Google Scholar
  12. 12.
    Maura G, Roccatagliata E, Ulivi M, Raiteri M (1988): Serotonin-glutamate interaction in rat cerebellum: involvement of 5-HT1 and 5-HT2 receptors. Eur J Pharmacol145: 31–38.PubMedCrossRefGoogle Scholar
  13. 13.
    Koenig JI, Gudelsky GA, Meltzer HY (1987): Stimulation of corticosterone and endorphin secretion in the rat by selective 5-HT receptor subtype activation. Eur J Pharmacol137: 1–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Lenahan SE, Seibel HR, Johnson JH (1987): Opiate-serotonin synergism stimulating luteinizing hormone release in estrogen-progesterone-primed ovariectomized rats: mediation by serotonin2 receptors. Endocrinology120: 1498–1502.PubMedCrossRefGoogle Scholar
  15. 15.
    Meltzer HY, Simonovic M, Gudelsky GA (1983): Effects of pirenperone and ketan- serin on rat prolactin secretion in vivo and in vitro. Eur J Pharmacol92: 83–89.PubMedCrossRefGoogle Scholar
  16. 16.
    Willoughby JO, Menadue MF, Liebelt H (1987): Activation of serotonin receptors in the medial basal hypothalamus stimulates growth hormone secretion in the unanaesthetized rat. Brain Res404: 319–322.PubMedCrossRefGoogle Scholar
  17. 17.
    Willoughby JO, Menadue MF, Liebelt H (1988): Activation of 5-HT 1 serotonin receptors in the medial basal hypothalamus stimulates prolactin secretion in the unanaesthetized rat. Neuroendocrinology47: 83–87.PubMedCrossRefGoogle Scholar
  18. 18.
    Heninger GR, Charney DS, Smith A (1987): Effects of serotonin receptor agonists and antagonists on neuroendocrine function in rhesus monkeys. Soc Neurosci Abstracts13: 801.Google Scholar
  19. 19.
    Leff P, Martin GR (1986): Peripheral 5-HT2-like receptors. Can they be classified with the available antagonists? Br J Pharmacol88: 585–593.PubMedCrossRefGoogle Scholar
  20. 20.
    Arunlakshana O, Schild HO (1959): Some quantitative uses of drug antagonists. Br J Pharmacol14: 48–58.Google Scholar
  21. 21.
    Bradley PB, Humphrey PPA, Williams RH (1983): Are vascular ‘D’ and ‘5-HT2’ receptors for 5-hydroxytryptamine the same? Br J Pharmacol79: 295 P.Google Scholar
  22. 22.
    Van Nueten JM, Janssen PAJ, Van Beek J, Xhonneux R, Verbeuren TJ, Vanhoutte PM (1981): Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors.J Pharmacol Exp Ther218: 217–230.PubMedGoogle Scholar
  23. 23.
    Bradley PB, Humphrey PPA, Williams RH (1985): Tryptamine-induced vasoconstriction responses in rat caudal arteries are mediated predominantly via 5-hydroxytrypta- mine receptors. Br J Pharmacol84: 919–925.PubMedCrossRefGoogle Scholar
  24. 24.
    Hicks PE, Langer SZ (1983): Antagonism by tetrahydro-ß-carboline of the vasoconstrictor responses to tryptamine in rat tail arteries. Eur J Pharmacol96: 145–149.PubMedCrossRefGoogle Scholar
  25. 25.
    Marwood JF, Stokes GS (1983): Vascular smooth muscle serotonin and a-adrenocep- tors. Clin Exp Pharmacol Physiol10: 265–267.PubMedCrossRefGoogle Scholar
  26. 26.
    Mecca TE, Webb RC (1984): Vascular responses to serotonin in steroid hypertensive rats. Hypertension6: 887–892.PubMedCrossRefGoogle Scholar
  27. 27.
    Cohen ML, Mason N, Wiley KS, Fuller RW (1983): Further evidence that vascular serotonin receptors are of the 5HT2 type. Biochem Pharmacol32: 567–570.PubMedCrossRefGoogle Scholar
  28. 28.
    Lemberger HF, Mason N, Cohen ML (1984): 5HT2 receptors in the rat portal vein: desensitization following cumulative serotonin addition. Life Sci 35: 71–77.PubMedCrossRefGoogle Scholar
  29. 29.
    Doggrell SA (1987): The effects of drugs on the contractile responses of the rat portal vein to phenylephrine and 5-hydroxytryptamine. Clin Exp Pharmacol PhysiolSuppl. 10: 34–35.Google Scholar
  30. 30.
    Cohen ML, Schenck KW, Colbert W, Wittenauer L (1985): Role of 5-HT2 receptors in serotonin-induced contractions of nonvascular smooth muscle. J Pharmacol Exp Ther232: 770–774.PubMedGoogle Scholar
  31. 31.
    Humphrey PPA, Feniuk W, Watts AD (1982): Ketanserin—a novel antihypertensive drug? J Pharm Pharmacol34: 541.PubMedCrossRefGoogle Scholar
  32. 32.
    Feniuk W, Humphrey PPA, Perren MJ, Watts AD (1985): A comparison of 5- hydroxytryptamine receptors mediating contraction in rabbit aorta and dog saphenous vein: evidence for different receptor types obtained by use of selective agonists and antagonists. Br J Pharmacol86: 697–704.PubMedCrossRefGoogle Scholar
  33. 33.
    Sutherland RMcD, Fishburn PA, Phillips CA, Mylecharane EJ (1989): The actions of ketanserin in smooth muscle preparations (in preparation).Google Scholar
  34. 34.
    Ichida S, Hayashi T, Terao M (1983): Selective inhibition by ketanserin and spiroperidol of 5-HT-induced myometrial contraction Eur J Pharmacol96: 155–158.PubMedCrossRefGoogle Scholar
  35. 35.
    Van Nueten JM, Janssen PAJ, De Ridder W, Vanhoutte PM (1982): Interaction between 5-hydroxytryptamine and other vasoconstrictor substances in the isolated femoral artery of the rabbit; effect of ketanserin (R 41 468). Eur J Pharmacol77: 281–287.PubMedCrossRefGoogle Scholar
  36. 36.
    Cohen RA (1986): Contractions of isolated canine coronary arteries resistant to S2-serotonergic blockade. J Pharmacol Exp Ther237: 548–552.PubMedGoogle Scholar
  37. 37.
    Lemoine H, Kaumann AJ (1986): Allosteric properties of 5-HT2 receptors in tracheal smooth muscle. Naunyn-Schmiedebergs Arch Pharmacol333: 91–97.PubMedCrossRefGoogle Scholar
  38. 38.
    Forster C, Whalley ET (1982): Analysis of the 5-hydroxytryptamine induced contraction of the human basilar arterial strip compared with the rat aortic strip in vitro. Naunyn-Schmiedebergs Arch Pharmacol319: 12–17.PubMedCrossRefGoogle Scholar
  39. 39.
    Apperley E, Humphrey PPA, Levy GP (1976): Receptors for 5-hydroxytryptamine and noradrenaline in rabbit isolated ear artery and aorta. Br J Pharmacol58: 211–221.PubMedCrossRefGoogle Scholar
  40. 40.
    Stollak JS, Furchgott RF (1983): Use of selective antagonists for determining the types of receptors mediating the actions of 5-hydroxytryptamine and tryptamine in the isolated rabbit aorta.J Pharmacol Exp Ther224: 215–221.Google Scholar
  41. 41.
    Apperley E, Feniuk W, Humphrey PPA, Levy GP (1980): Evidence for two types of excitatory receptor for 5-hydroxytryptamine in dog isolated vasculature. Br J Pharmacol68: 215–224.PubMedCrossRefGoogle Scholar
  42. 42.
    Black JW, Brazenor RM, Gerskowitch VP, Leff P (1983): The problem of insurmountable antagonism in 5-hydroxytryptamine receptor classification Br J Pharmacol80: 607 P.Google Scholar
  43. 43.
    Cohen ML, Fuller RW, Wiley KS (1981): Evidence for 5-HT2 receptors mediating contraction in vascular smooth muscle. J Pharmacol Exp Ther218: 421–425.PubMedGoogle Scholar
  44. 44.
    Maayani S, Wilkinson CW, Stollak JS (1984): 5-hydroxytryptamine receptor in rabbit aorta: characterization by butyrophenone analogs. J Pharmacol Exp Ther 229: 346–350.PubMedGoogle Scholar
  45. 45.
    Clancy BM, Maayani S (1985): 5-hydroxytryptamine receptor in isolated rabbit aorta: characterization with tryptamine analogs. J Pharmacol Exp Ther 233: 761–769.PubMedGoogle Scholar
  46. 46.
    Black JL, French RJ, Mylecharane EJ (1981): Receptor mechanisms for 5-hydroxytryptamine in rabbit arteries. Br J Pharmacol74: 619–626.PubMedCrossRefGoogle Scholar
  47. 47.
    Wrigglesworth SJ (1983): Heterogeneity of 5-hydroxytryptamine receptors in the rat uterus and stomach strip. Br J Pharmacol80: 691–697.PubMedCrossRefGoogle Scholar
  48. 48.
    Cohen ML, Fuller RW, Kurz KD (1983): LY53857, a selective and potent serotonergic (5-HT2) receptor antagonist, does not lower blood pressure in the spontaneously hypertensive rat. J Pharmacol Exp Ther227: 327–332.PubMedGoogle Scholar
  49. 49.
    Ben-Harari RR, Dalton B, Kaplan J, Maayani S (1987): Kinetic characterization of the response to 5-hydroxytryptamine in airway and vascular tissues. Soc Neurosci Abstracts13: 343.Google Scholar
  50. 50.
    Fong I, Philips CA, Mylecharane EJ (1987). 5-Hydroxytryptamine receptor subtypes in rabbit common carotid artery, guinea-pig trachea and rat stomach fundus preparations. Clin Exp Pharmacol Physiol Suppl. 11:189.Google Scholar
  51. 51.
    Leff P, Martin GR, Morse JM (1987): Differential classification of vascular smooth muscle and endothelial cell 5-HT receptors by use of tryptamine analogues. Br J Pharmacol91: 321–331.PubMedCrossRefGoogle Scholar
  52. 52.
    Kaumann AJ (1983): Yohimbine and rauwolscine inhibit 5-hydroxytryptamine-induced contraction of large coronary arteries of calf through blockade of 5-HT2 receptors. Naunyn-Schmiedebergs Arch Pharmacol323: 149–154.PubMedCrossRefGoogle Scholar
  53. 53.
    Frenken M, Kaumann AJ (1984): Interaction of ketanserin and its metabolite ketanserinol with 5-HT2 receptors in pulmonary and coronary arteries of calf. Naunyn- Schmiedebergs Arch Pharmacol326: 334–339.PubMedCrossRefGoogle Scholar
  54. 54.
    Kaumann AJ, Frenken M (1985). A paradox: the 5-HT2-receptor antagonist ketanserin restores the 5-HT-induced contraction depressed by methysergide in large coronary arteries of calf. Allosteric regulation of 5-HT2-receptors. Naunyn-Schmiedebergs Arch Pharmacol328: 295–300.PubMedCrossRefGoogle Scholar
  55. 55.
    Engel G, Hoyer D, Kalkman H, Wick MB (1985): Pharmacological similarity between the 5-HT-D-receptor on the guinea-pig ileum and the 5-HT2 binding site. Br J Pharmacol84: 106 P.Google Scholar
  56. 56.
    Eccles NK, Grimmer AJ, Leathard HL (1981): Action of ketanserin, a new 5-hydroxytryptamine antagonist, on human isolated blood vessels. Br J Pharmacol 74: 83IP–832P.Google Scholar
  57. 57.
    Müller-Schweinitzer E (1984): Alpha-adrenoceptors, 5-hydroxytryptamine receptors and the action of dihydroergotamine in human venous preparations obtained during saphenectomy procedures for varicose veins. Naunyn-Schmiedebergs Arch Pharmacol327: 299–303.PubMedCrossRefGoogle Scholar
  58. 58.
    Docherty JR, Hyland L (1986): An examination of 5-hydroxytryptamine receptors in human saphenous vein. Br J Pharmacol89: 77–81.PubMedCrossRefGoogle Scholar
  59. 59.
    Clineschmidt BV, Reiss DD, Pettibone DJ, Robinson JL (1985): Characterization of 5-hydroxytryptamine receptors in rat stomach fundus. J Pharmacol Exp Ther235: 696–708.PubMedGoogle Scholar
  60. 60.
    McGrath JC, MacLennan SJ, Stuart-Smith K (1985): Characterization of the receptor mediating contraction of human umbilical artery by 5-hydroxytryptamine. Br J Pharmacol84: 199–202.PubMedCrossRefGoogle Scholar
  61. 61.
    McGrath JC, MacLennan SJ (1986): Oxygen modifies the potency of 5-HT, and of 5-HT antagonists, in human umbilical artery (HUA). Br J Pharmacol88: 320 P.Google Scholar
  62. 62.
    MacLennan SJ, McGrath JC (1986): Evidence for “5-HT1-like” receptors in human umbilical artery (HUA). Br J Pharmacol89: 587 P.Google Scholar
  63. 63.
    Tuncer M, Dogan N, Oktay S, Kayaalp SO (1985): Receptor mechanisms for 5-hydroxytryptamine in isolated human umbilical artery and vein. Arch Int Pharmaco- dyn Ther276: 17–27.Google Scholar
  64. 64.
    Brazenor RM, Angus JA (1981): Ergometrine contracts isolated coronary arteries by a serotonergic mechanism: no role for alpha adrenoceptors. J Pharmacol Exp Ther218: 530–536.PubMedGoogle Scholar
  65. 65.
    Brazenor RM, Angus JA (1982): Actions of serotonin antagonists on dog coronary artery. Eur J Pharmacol81: 569–576.PubMedCrossRefGoogle Scholar
  66. 66.
    Porquet M-F, Pourrias B, Santamaria R (1982): Effects of 5-hydroxytryptamine on canine isolated coronary arteries. Br J Pharmacol75: 305–310.PubMedCrossRefGoogle Scholar
  67. 67.
    Frenken M, Kaumann AJ (1985): Ketanserin causes surmountable antagonism of 5-hydroxytryptamine-induced contractions of large coronary arteries of dog. Naunyn- Schmiedebergs Arch Pharmacol328: 301–303.PubMedCrossRefGoogle Scholar
  68. 68.
    Houston DS, Vanhoutte PM (1988): Comparison of serotonergic receptor subtypes on the smooth muscle and endothelium of the canine coronary artery. J Pharmacol Exp Ther244: 1–10.PubMedGoogle Scholar
  69. 69.
    Engel G, Göthert M, Müller-Schweinitzer E, Schlicker E, Sistonen L, Stadler PA (1983): Evidence for common pharmacological properties of [3H]-5-hydroxytryptamine binding sites, presynaptic 5-hydroxytryptamine autoreceptors in CNS and inhibitory presynaptic 5-hydroxytryptamine receptors on sympathetic nerves. Naunyn-Schmiede- bergs Arch Pharmacol324: 116–124.CrossRefGoogle Scholar
  70. 70.
    Kilbinger H, Pfeuffer-Friedrich I (1985): Two types of receptors for 5-hydroxytryptamine on the cholinergic nerves of the guinea-pig myenteric plexus. Br J Pharmacol85: 529–539.PubMedCrossRefGoogle Scholar
  71. 71.
    Molderings GJ, Fink K, Schlicker E, Gothert M (1987): Inhibition of noradrenaline release via presynaptic 5-HT1B receptors of the rat vena cava. Naunyn-Schmiedebergs Arch Pharmacol336: 245–250.PubMedGoogle Scholar
  72. 72.
    Müller-Schweinitzer E, Engel G (1983): Evidence for mediation by 5-HT2 receptors of 5-hydroxytryptamine-induced contraction of canine basilar artery. Naunyn-Schmiede- bergsArch Pharmacol324: 287–292.CrossRefGoogle Scholar
  73. 73.
    Peroutka SJ, Noguchi M, Tolner DJ, Allen GS (1983): Serotonin-induced contraction of canine basilar artery: mediation by 5-HT, receptors. Brain Res259: 327–330.PubMedCrossRefGoogle Scholar
  74. 74.
    Peroutka SJ, Kuhar MJ (1984): Autoradiographic localization of 5-HT1, receptors to human and canine basilar arteries. Brain Res310: 193–196.PubMedCrossRefGoogle Scholar
  75. 75.
    Peroutka SJ, Huang S, Allen GS (1986): Canine basilar artery contractions mediated by 5-hydroxytryptamine1A receptors. J Pharmacol Exp Ther237: 901–906.PubMedGoogle Scholar
  76. 76.
    Cohen ML, Colbert WE (1986): Relationship between receptors mediating serotonin (5-HT) contractions in the canine basilar artery to 5-HT1, 5-HT2 and rat stomach fundus 5-HT receptors. J Pharmacol Exp Ther237: 713–718.PubMedGoogle Scholar
  77. 77.
    Taylor EW, Duckies SP, Nelson DL (1986): Dissociation constants of serotonin agonists in the canine basilar artery correlate to Ki values at the 5-HT1A binding site. J Pharmacol Exp Ther236: 118 - 125.PubMedGoogle Scholar
  78. 78.
    Frenken M, Kaumann AJ (1986): Surmountable antagonism by ketanserin of 5-hydroxytryptamine-induced contractions in dog basilar artery. Br J Pharmacol89: 550 P.Google Scholar
  79. 79.
    Peroutka SJ, Lebovitz RM, Snyder SH (1981): Two distinct central serotonin receptors with different physiological functions. Science212: 827–829.PubMedCrossRefGoogle Scholar
  80. 80.
    Leysen JE, Niemegeers CJE, Van Nueten JM, Laduron PM (1982): [3H] Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites: binding properties, brain distribution, and functional role. Mol Pharmacol 21: 301–314.PubMedGoogle Scholar
  81. 81.
    Martin LL, Sanders-Bush E (1982): Comparison of the pharmacological characteristics of 5HT1 and 5HT2 binding sites with those of serotonin autoreceptors which modulate serotonin release. Naunyn-Schmiedebergs Arch Pharmacol321: 165–170.PubMedCrossRefGoogle Scholar
  82. 82.
    Cohen ML, Wittenauer LA (1985): Relationship between serotonin and tryptamine receptors in the rat stomach fundus. J Pharmacol Exp Ther233: 75–79.PubMedGoogle Scholar
  83. 83.
    Pazos A, Hoyer D, Palacios JM (1985): Mesulergine, a selective serotonin-2 ligand in the rat cortex, does not label these receptors in porcine and human cortex: evidence for species differences in brain serotonin-2 receptors. Eur J Pharmacol106: 531–538.CrossRefGoogle Scholar
  84. 84.
    Engel G, Göthert M, Hoyer D, Schlicker E, Hillenbrand K (1986): Identity of inhibitory presynaptic 5-hydroxytryptamine (5-HT) autoreceptors in the rat brain cortex with 5-HT1B binding sites. Naunyn-Schmiedebergs Arch Pharmacol332: 1–7.PubMedCrossRefGoogle Scholar
  85. 85.
    Schotte A, Maloteaux JM, Laduron PM (1983): Characterization and regional distribution of serotonin S2-receptors in human brain. Brain Res276: 231–235.PubMedCrossRefGoogle Scholar
  86. 86.
    McBride PA, Mann JJ, McEwen B, Biegon A (1983): Characterization of serotonin binding sites on human platelets. Life Sci33: 2033–2041.PubMedCrossRefGoogle Scholar
  87. 87.
    Leysen JE, de Chaffoy de Courcelles D, De Clerck F, Niemegeers CJE, Van Nueten JM (1984): Serotonin-S2 receptor binding sites and functional correlates. Neuropharmacology23: 1493–1501.PubMedCrossRefGoogle Scholar
  88. 88.
    Ichida S, Hayashi T, Kita T, Murakami T (1985): Estradiol-induced increase of specific [3H] ketanserin binding sites on rat uterine membranes. Eur J Pharmacol 108: 257–264.PubMedCrossRefGoogle Scholar
  89. 89.
    Shannon, M, Battaglia G, Glennon RA, Titeler M (1984): 5-HT, and 5-HT2 binding properties of the hallucinogen l-(2,5-dimethoxyphenyl)-2-aminopropane (2,5-DMA). Eur J Pharmacol 102:23–29.PubMedCrossRefGoogle Scholar
  90. 90.
    Lyon RA, Titeler M, Glennon RA (1987): LSD and phenylisopropylamine hallucinogen interactions with multiple radiolabeled brain serotonin receptors. Soc Neurosci Abstracts13: 1183.Google Scholar
  91. 91.
    Wang SS, Peroutka SJ (1987): 2,5-Dimethoxy-4-bromoamphetamine (DOB) interactions with 5-HT receptor subtypes. Soc Neurosci Abstracts13: 1237.Google Scholar
  92. 92.
    Schechter LE, Simansky KJ (1987): l-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane HC1 (DOI), a selective 5-HT2 agonist, exerts an anorexic action in rats that is prevented by LY53857, a selective 5-HT2 antagonist. Soc Neurosci Abstracts13: 1339.Google Scholar
  93. 93.
    McCall RB, Harris LT (1988): 5-HT2 receptor agonists increase spontaneous sympathetic nerve discharge. Eur J Pharmacol 151:113–116.PubMedCrossRefGoogle Scholar
  94. 94.
    Glennon RA, Seggel MR, Soine WH, Davis KH, Lyon RA, Titeler M (1987): [125DOI]: a new radiolabel for 5-HT2 serotonin sites. Soc. Neurosci Abstracts13: 1181.Google Scholar
  95. 95.
    Nelson DL, Killam AL, Lambert G, Nikam SS, Week B, Martin AR (1987): Structure-activity relationships of a series of tetrahydropyridylindoles at serotonin1A and serotonin2 receptors. Soc Neurosci Abstracts13: 1236.Google Scholar
  96. 96.
    Hirata M, Imamoto T, Shibouta Y, Kurihara Y, Kito G, Sugihara H (1986): A selective S2-serotonin blocker, CV-5197, a benzoxathiepin analog. Blood Vessels23: 76.Google Scholar
  97. 97.
    Blackburn TP, Cox B, Pearce RJ, Thornber CW (1987): In vivo pharmacology of ICI 169,369—a new 5-HT2 antagonist. Br J Pharmacol90: 256 P.Google Scholar
  98. 98.
    Blackburn TP, Thornber CW, Pearce RJ, Cox B (1988): In vitro studies with ICI 169,369, a chemically novel 5-HT antagonist. Eur J Pharmacol150: 247–256.PubMedCrossRefGoogle Scholar
  99. 99.
    Blackburn TP, Cox B, Grant TL, Growcott JW (1987): ICI 169369 is an antagonist of 5-HT in tissues claimed to contain 5-HT1A and 5-HT1c receptors. Soc Neurosci Abstracts13: 801.Google Scholar
  100. 100.
    Cummings SA, Groszmann RJ, Kaumann AJ (1986): Hypersensitivity of mesenteric veins to 5-hydroxytryptamine- and ketanserin-induced reduction of portal pressure in portal hypertensive rats. Br J Pharmacol89: 501–513.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1990

Authors and Affiliations

  • E. J. Mylecharane

There are no affiliations available

Personalised recommendations